Supplemental material
Expert Opinion on Drug Safety
Volume 21, 2022 - Issue 3
Original research
Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials
, , , , , 
& show all
Daisuke Yabef Department of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan;g Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kobe, Japan;h Division of Molecular and Metabolic Medicine, Department of Physiology and Cell Biology, Kobe University Graduate School of Medicine, Kobe, Japan;i Center for Healthcare Information Technology (C-HIT), Tokai National Higher Education and Research System, Nagoya, Japanhttps://orcid.org/0000-0002-5334-7687View further author information
https://orcid.org/0000-0002-5334-7687View further author information & show all